Health Economics›Low-grade serous ovarian cancer›Relapsed or recurrent disease

Relapsed or recurrent disease

Low-grade serous ovarian cancer · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Selumetinib monotherapy Variant #01	—	R 308 264	28d	~3.7 mo	—	~5	~R 1 541 319 PFS proxy · indirect	1
Trametinib monotherapy Variant #01	—	R 26 396	28d	~13.0 mo	—	~15	~R 395 933 PFS proxy · indirect	1
Pegylated liposomal doxorubicin monotherapy Variant #01	—	R 15 300	28d	~8.9 mo	—	~10	~R 153 000 PFS proxy · indirect	2
Topotecan monotherapy Variant #01	—	R 11 563	21d	~8.9 mo	—	~13	~R 150 322 PFS proxy · indirect	2
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	~8.9 mo	—	~10	~R 22 195 PFS proxy · indirect	2
Tamoxifen monotherapy Variant #06	—	R 410	28d	~7.2 mo	—	~8	~R 3 279 PFS proxy · indirect	1
Letrozole monotherapy Variant #01	—	R 371	28d	~7.2 mo	—	~8	~R 2 967 PFS proxy · indirect	1

7 of 7 regimens shown